胸腔内注射尿激酶治疗初治结核性胸膜炎的疗效观察  

Observation of intrapleural urokinase in treatment of tuberculous pleural effusion

作　　者：王瑾[1] 胡斌[1] 周超[1] 丁红梅[1] 方平[1] 

机构地区：[1]安徽省铜陵市人民医院呼吸内科,244000

出　　处：《临床肺科杂志》2006年第4期463-464,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察胸腔内注射尿激酶治疗结核性胸膜炎的效果。方法37例结核性粘连包裹性胸膜炎患者随机分为治疗组(18例)对照组(19例),胸腔内置入中心静脉导管,抽尽胸水,治疗组胸腔内注入NS100ml+尿激酶10万IU,其他治疗与对照组相同。结果治疗组抽胸液总量(3361±1208)ml,对照组(2485±1455)ml(P>0.05),3个月后测胸膜厚度,治疗组(1.24±0.30)mm,对照组(1.56±0.40)mm(P<0.01),胸膜粘连发生率治疗组16.7%,对照组47.4%(P<0.05)。结论胸膜腔内注入尿激酶能有效降低胸膜肥厚和粘连,与对照组相比差异有显著性。[ Abstract] Objective To observe the effects of intrapleural urokinase in the treatment of pleural thickening and loculated pleural effusion. Methods Thirty-seven cases of tuberculous pleural effusions were randomized into two groups ： treatment （ n = 18 ） and control groups （n = 19）. The palienls in lhe lreatment group were injected with urokinase 100000 IU in 100 ml normal saline intrapleurally, be- sides the regular treatment that the controls were given. Results The mean volume of fluid drained in the treatment group was （3361 ＋ 1208） ml, while it was （2485 ＋ 1455） ml in lhe control group （P 〈0. 05 ）. The mean thickness of pleural in the treatment group was （ 1.24 ± 0.30 ） taro after 3 month treatment, whereas in the control group it was （ 1.56 ±0.40） mm （ P 〈 0. 01 ）. the incidence of pleural adhesion and loculation in the treatment group was 16.7% , whereas in the controls it was 47.4% （ P 〈 0.05）. Conclusion Intrapleural urokinase can prevent pleural thickening and adhesion. It is an effective therapy in the treatment of tuberculous pleural effusion.

关 键 词：尿激酶 结核 胸膜炎 肥厚 粘连 胸腔内注射 

分 类 号：R521.7[医药卫生—内科学] R743.35[医药卫生—临床医学]